Table 4.
Nonhistone acetylation in hypoxia.
| Name | Substrate | Effect | Cell type (cell line) | O2 (%) | Ref. |
|---|---|---|---|---|---|
| Histone acetyltransferases | |||||
| P300/CBP | HIF-1α K709 | Increase in HIF-1α stability | Embryonic kidney cell (HEK293T) | 1 | 59 |
| Glioblastoma (LN229) | 60 | ||||
| PCAF | HIF-1α K674 | Increase in HIF-1α stability | Fibrosarcoma (HT1080) | 1 | 61 |
| ELP3 | PAK1 K420 | Inhibition of PAK1 dimerization leading to enhanced PAK1 activity | Glioblastoma (LN229) | Not specified | 62 |
| MYST1 | N-terminal of HIF-1α | Decrease in HIF-1α stability | Hepatocellular carcinoma (Huh-7, Hep3B) | CoCl2 | 64 |
| Histone deacetylases | |||||
| HDAC2 | HIF-1α K532 | Increase in HIF-1α stability | Oral squamous cell carcinoma (HSC-3) | Not specified | 72 |
| HDAC3 | P-TEFb | Inhibition of transcription elongation | Cervical cancer (HeLa) | 0.5 | 74 |
| HDAC4 | K10, K11, K12, K19, and K21 of HIF-1α | Increase in HIF-1α stability | Hepatocellular carcinoma (Hep3Bc1), Prostate cancer (C42B) | 1 | 77 |
| HDAC5 | HSP70 | Increase in mature HIF-1α accumulation | Hepatocellular carcinoma (Hep3B), cervical cancer (HeLa) | 1 | 79 |
| HDAC6 | HSP70 | Increase in HIF-1α stability and transactivity in a VHL-independent manner | Embryonic fibroblast (MEF) | 1 | 81 |
| Lung cancer (A549) | 1 | 80 | |||
| Renal cell carcinoma (UMRC2) | (CoCl2) | 124 | |||
| SIRT1 | HIF-1α K674 | Suppression of HIF-1α target gene | Fibrosarcoma (HT1080) | 1 | 61 |
| Renal proximal tubule cell (HK2) | 84 | ||||
| SIRT1 | HIF-2α K385, K685, and K741 | Activation of HIF-2α transactivity | Hepatocellular carcinoma (Hep3B) | 1 | 57,85 |
| SIRT2 | HIF-1α K709 | Decrease in HIF-1α stability (Induction of HIF-1α degradation) | Cervical cancer (HeLa) | 1 | 86 |
| B cell precursor leukemia (NALM-6) | 87 | ||||
| SIRT3 | FOXO3 | Inhibition of FOXO3 degradation | Endothelial cell (HUVEC) | 2 | 88 |